Study of the Utility of Myeloid Cell Nuclear Differentiation Antigen (MNDA) in the Diagnosis of Marginal Zone Lymphoma.
Humans
Adult
Leukemia, Lymphocytic, Chronic, B-Cell
/ metabolism
Lymphoma, B-Cell, Marginal Zone
/ diagnosis
B-Lymphocytes
/ pathology
Lymphoma, Follicular
/ diagnosis
Lymphoma, Mantle-Cell
/ pathology
Waldenstrom Macroglobulinemia
/ metabolism
Antigens, Differentiation, Myelomonocytic
/ metabolism
Myeloid Cells
/ metabolism
Transcription Factors
/ metabolism
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
29
07
2022
accepted:
10
01
2023
medline:
7
4
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Myeloid cell nuclear differentiation antigen (MNDA) is normally expressed on myelomonocytic cells and a subset of B lymphocytes. It was found to be differentially expressed between nodal marginal zone lymphoma (MZL) and follicular lymphoma (FL). However, MNDA has not been widely used as a diagnostic marker in clinical practice. To validate its utility, we studied the expression of MNDA by immunohistochemistry in 313 cases of small B-cell lymphomas. Our results showed that MNDA was positive in 77.9% of MZL, 21.9% of mantle cell lymphoma, 28.9% of small lymphocytic lymphoma/chronic lymphocytic leukemia, 2.6% of FL, and 25% of lymphoplasmacytic lymphoma. MNDA positivity varied from 68.0% to 84.0% among the 3 MZL subtypes, with extranodal MZL having the highest percentage. There was a statistically significant difference in MNDA expression between MZL and FL, mantle cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, or lymphoplasmacytic lymphoma. CD43 expression was slightly more frequent in MNDA-negative MZL than in MNDA-positive MZL. Combined use of CD43 and MNDA improved the diagnostic sensitivity for MZL from 77.9% to 87.8%. There was a trend of positive correlation between MNDA and p53 in MZL. In conclusion, MNDA is preferentially expressed in MZL among small B-cell lymphomas and it is a useful marker for the differentiation of MZL and FL.
Identifiants
pubmed: 36867739
doi: 10.1097/PAI.0000000000001115
pii: 00129039-202304000-00004
pmc: PMC10072213
doi:
Substances chimiques
Antigens, Differentiation, Myelomonocytic
0
MNDA protein, human
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-223Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues Revised, 4th ed. IARC; 2017.
Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol. 2011;136:211–225.
Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol. 2003;27:762–771.
Naresh KN. Nodal marginal zone B-cell lymphoma with prominent follicular colonization-difficulties in diagnosis: a study of 15 cases. Histopathology. 2008;52:331–339.
Kojima M, Nakamura S, Murase T, et al. Follicular colonization of nodal marginal-zone B-cell lymphoma resembling follicular lymphoma: report of 6 cases. Int J Surg Pathol. 2005;13:73–78.
Kanellis G, Roncador G, Arribas A, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23:1847–1857.
Johnstone RW, Trapani JA. Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol. 1999;19:5833–5838.
Miranda RN, Briggs RC, Shults K, et al. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol. 1999;30:1040–1049.
Metcalf RA, Ahmad Monabati A, Vyas M, et al. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. Hum Pathol. 2014;45:1730–1736.
Wang Z, Cook JR. IRTA1 and MNDA Expression in marginal zone lymphoma utility in differential diagnosis and implications for classification. Am J Clin Pathol. 2019;151:337–343.
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–1253.
Boyd SD, Natkunam Y, Allen JR, et al. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21:116–131.
Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111:488–494.
Manohar V, Peerani R, Tan B, et al. Myeloid cell nuclear differentiation antigen (MNDA) positivity in primary follicles: potential pitfall in the differentiation diagnosis with marginal zone lymphoma. Appl Immunohistochem Mol Morphol. 2020;28:384–388.
Fotouhi-Ardakani N, El Kebir D, Pierre-Charles N, et al. Role for myeloid nuclear differentiation antigen in the regulation of neutrophil apoptosis during sepsis. Am J Respir Crit Care Med. 2010;182:341–350.
Briggs RC, Shults KE, Flye LA, et al. Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosis. Cancer Res. 2006;66:4645–4651.
Asefa B, Dermott JM, Kaldis P, et al. p205, A potential tumor suppressor inhibits cell proliferation via multiple pathways of cell cycle regulation. FEBS Lett. 2006;580:1205–1214.
Gruszka-Westwood AM, Hamoudi RA, Matutes E, et al. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001;97:3552–3558.
Imamura J, Miyoshi J, Koeffler HP. P53 in hematologic malignancies. Blood. 1994;84:2412–2421.
Zeggai S, Harir N, Tou A, et al. Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study. J Gastrointest Oncol. 2016;7:462–468.